Development of an MRI/x-ray/ultrasound compatible marker for pre-operative breast tumour localization

This paper describes an in vitro investigation into the composition, structure and development of an magnetic resonance imaging (MRI), ultrasound (US) and x-ray imaging compatible marker for breast tumour localization. The marker is composed of 0.4–0.6 mm glass and iron-containing aluminium microspheres suspended in a gelatin matrix. The final form of the marker is a cylindrical shape 7 mm long with 2.05 mm diameter to facilitate delivery through a 12 gauge biopsy needle. To get optimal reflectivity for the US contrast, the glass microsphere concentration was found to be 40% by weight. US contrast is independent of marker orientation and the cylindrical shape made its US signal appearance distinctive thus ensuring confident identification. To control the MRI contrast, iron content was varied to generate a clear and local susceptibility signal void to reflect the marker position. Optimal iron content was found to be 52 µg iron which produced a clear signal void in spoiled gradient recalled MR images. The appearance of the susceptibility artefact is determined by the marker's shape, orientation and echo time. The final marker produces a dark artefact in MRI while appears as a clear hyperintense structure with acoustic shadowing in US images. The x-ray image showed the marker as a radio-opaque structure. This in vitro study demonstrates that the marker forms an alternative to traditional wire localization currently used for breast surgical procedures and creates new opportunities for US guided surgical procedures.

[1]  D. Fraker,et al.  Magnetic resonance imaging-guided biopsy of mammographically and clinically occult breast lesions , 2007, Annals of Surgical Oncology.

[2]  Ellen Warner,et al.  Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination , 2004, JAMA.

[3]  R. Birdwell,et al.  Clip or marker migration 5-10 weeks after stereotactic 11-gauge vacuum-assisted breast biopsy: report of two cases. , 2003, Radiology.

[4]  Max A Viergever,et al.  Passive tracking exploiting local signal conservation: The white marker phenomenon , 2003, Magnetic resonance in medicine.

[5]  Isabelle Bedrosian,et al.  Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging , 2003, Cancer.

[6]  E. Pisano,et al.  Factors predicting successful needle-localized breast biopsy. , 2003, Academic radiology.

[7]  M. Ernst,et al.  Wire localization of non-palpable breast lesions: out of date? , 2002, Breast.

[8]  D B Plewes,et al.  Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Makoske,et al.  Long-term outcomes of stereotactic breast biopsies. , 2000, The American surgeon.

[10]  T P O'Neill,et al.  Ultrasound-guided needle biopsy of the breast. , 1999, Surgery.

[11]  L. Fajardo,et al.  Placement of endovascular embolization microcoils to localize the site of breast lesions removed at stereotactic core biopsy. , 1998, Radiology.

[12]  R. J. Jackman,et al.  Needle-localized breast biopsy: why do we fail? , 1997, Radiology.

[13]  J. Schenck.  The role of magnetic susceptibility in magnetic resonance imaging: MRI magnetic compatibility of the first and second kinds. , 1996, Medical physics.

[14]  T. Rissanen,et al.  Wire localized biopsy of breast lesions: a review of 425 cases found in screening or clinical mammography. , 1993, Clinical radiology.

[15]  Dermott E. Cullen,et al.  Tables and graphs of photon-interaction cross sections from 0. 1 keV to 100 MeV derived from the LLL Evaluated-Nuclear-Data Library , 1978 .

[16]  F. A. Silber,et al.  ULTRASONIC TESTING OF MATERIALS , 1978 .